07 May COPD: Aclidinium Bromide (Tudorza Pressair) Has Favorable Safety Profile in Patients with CVD

MedicalResearch.com Interview with:

Dr. Wise

Robert A. Wise, M.D.
Professor of Medicine
Pulmonary and Critical Care
Johns Hopkins University School of Medicine
Baltimore, MD

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: There has been a lingering controversy about the safety of long-acting anti-muscarinic agents (LAMA) as maintenance treatment for COPD in patients who have increased cardiovascular risk.  This study enrolled participants with COPD who also had increased cardiovascular risk or known cardiovascular disease.  Participants were randomly treated with either aclidinium bromide (Tudorza Pressair) or placebo.

Over 3 years of follow up there was no increased risk of adverse cardiovascular events.  Moreover, the medication had a significant benefit in terms of reducing exacerbations and COPD hospitalizations.

MedicalResearch.com: What should readers take away from your report?

Response: Aclidinium is a safe and effective maintenance treatment for patients with COPD regardless of background cardiovascular risk or cardiovascular disease.  Aclidinium has a favorable risk-benefit profile in this population.  

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Further research is needed to better understand which patients with COPD respond best to treatments like aclidinium, particularly when combined with other maintenance treatments.

Disclosures: This study was funded by Forest Laboratories, Astra-Zeneca, and Circassia.  Robert Wise, as well as several of the other authors have received consulting fees from the study sponsors or are employed by Astra-Zeneca.  Dr. Wise’s conflict of interest is managed by the Johns Hopkins University School of Medicine Office of Policy Coordination.

Citation:

Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. JAMA. 2019;321(17):1693–1701. doi:10.1001/jama.2019.4973

[wysija_form id=”3″]

[last-modified]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on May 7, 2019 by Marie Benz MD FAAD